Preparation and quality control of clinic scale 188W-188Re generator

188Re is an excellent candidate for the radionuclide therapy, since it is easily obtained as a ''no-carrier-added'' radioisotope from a 188W-188Re generator. The half-life of 16.9 hours is suitable for tumor treatment and of benefit to minimize toxicity to whole body; Beta emissions with energies of 2.12 MeV (71.6%) and 1.97 MeV (25.1%) are suitable for therapy and the gamma emission of 155 keV (15%) allows imaging and dosimetry. The drug for tumor therapy has been a highlight of the new drug development in recent years. The radionuclide therapy has shown significant effectiveness in the treatment of various cancers. 188W-188Re generator could conveniently provide high levels of carrier-free rhenium-188 at low cost for the treatment of a variety of cancers, cardiovascular diseases as well as the marrow transplantation. (orig.)